Met Life Investment Management, LLC Protagonist Therapeutics, Inc Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 35,798 shares of PTGX stock, worth $1.38 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,798
Previous 33,805
5.9%
Holding current value
$1.38 Million
Previous $1.52 Million
9.08%
% of portfolio
0.01%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$228 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$222 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$212 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$162 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$128 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.89B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...